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Abstract
Background: It has been shown previously that it is possible to obtain growth of Plasmodium falciparum in human
erythrocytes grafted in mice lacking adaptive immune responses by controlling, to a certain extent, innate defences with
liposomes containing clodronate (clo-lip). However, the reproducibility of those models is limited, with only a proportion of
animals supporting longstanding parasitemia, due to strong inflammation induced by P. falciparum. Optimisation of the
model is much needed for the study of new anti-malarial drugs, drug combinations, and candidate vaccines.
Materials/Methods: We investigated the possibility of improving previous models by employing the intravenous route (IV)
for delivery of both human erythrocytes (huRBC) and P. falciparum, instead of the intraperitoneal route (IP), by testing
various immunosuppressive drugs that might help to control innate mouse defences, and by exploring the potential
benefits of using immunodeficient mice with additional genetic defects, such as those with IL-2Rc deficiency (NSG mice).
Results: We demonstrate here the role of aging, of inosine and of the IL-2 receptor c mutation in controlling P. falciparum
induced inflammation. IV delivery of huRBC and P. falciparum in clo-lip treated NSG mice led to successful infection in 100%
of inoculated mice, rapid rise of parasitemia to high levels (up to 40%), long-lasting parasitemia, and consistent results from
mouse-to-mouse. Characteristics were closer to human infection than in previous models, with evidence of synchronisation,
partial sequestration, and receptivity to various P. falciparum strains without preliminary adaptation. However, results show
that a major IL-12p70 inflammatory response remains prevalent.
Conclusion: The combination of the NSG mouse, clodronate loaded liposomes, and IV delivery of huRBC has produced a
reliable and more relevant model that better meets the needs of Malaria research.
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Introduction
The development of a small laboratory model capable of
tolerating and sustaining human malaria infection has almost
unlimited applications in areas such as parasite biology, novel drug
development and vaccine discovery.
Currently, the majority of in vivo investigations into malaria
biology are performed using rodent malaria species such as P.
berghei, and P. yoelii that are much easier to handle however, their
relevance to human malaria has been questioned [1,2,3]. A
convenient model capable of sustaining P. falciparum would
undoubtedly be beneficial. For example, such a model could
serve to harmonise in vitro studies that use P. falciparum in culture,
with the in vivo models that presently use rodent species. While
these approaches are complementary, the current mismatch of
Plasmodium species is a very serious limitation. With the
development of resistance against all existing anti-malarial drugs,
the need for better tools to discover and develop novel classes and
combinations of anti-malarials is imperative [4,5].
The advent of several new mouse strains with genetic immune
deficiencies has greatly benefited the development of a small
laboratory malaria model, and results have shown that such a
model is indeed both achievable and useful [6,7,8,9,10].
Experiments performed so far have used mouse strains such as
SCID, NIH III (Beige Xid Nude), and NOD/SCID, together with
pharmacological agents to control their remaining innate defences,
or mouse adapted parasites. It was shown that by grafting them
with either human erythrocytes [6,11] or human hepatocytes [12]
these animals can support, respectively, the asexual blood cycle, or
the intra-hepatic cycle of the human parasite P. falciparum.
However, on a day-to-day basis they are quite cumbersome to
manage [6,11], and this onus, combined with their currently poor
reproducibility of successful infection, limits their usefulness, and is
likely to have contributed to the persistent use of rodent Plasmodium
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reasons of convenience rather than scientific merit.
A main barrier to achieving an improved, workable P. falciparum
mouse model is the strong pro-inflammatory effect of the parasite
itself. In humans the asexual erythrocytic stages of P. falciparum are
known to result in a systemic inflammatory process that is
responsible for many of the symptoms of the disease [13].
Although the two situations differ in several respects, a similar
inflammatory response was observed in immunodeficient mice,
lacking T and B cells. In this case, as recently described [6], P.
falciparum triggers strong pro-inflammatory reactions in monocytes
and macrophages, contributing to partial control of the parasite
and the human erythrocyte (huRBC) graft.
A second significant practical problem with all existing models
developed to date is that huRBC are injected by the intra-peritoneal
(IP) route, which relies on the successful migration of huRBC into
the blood stream across the peritoneum. This is a process that is not
properlyunderstood,and, inturn,this preventsanyrational analysis
and improvement of the model. Existing models have been useful in
proving the concept that P.falciparum can survive in a small rodent
model, however they have also shown that unless inordinate
volumes of blood are injected IP daily [11,14], trans-peritoneal
passage to the peripheral blood is uneven, particularly in the long
term. This leads to important variations from one animal to the
other, most likely related to the inflammatory reaction triggered by
high parasite loads, as shown previously [6].
With these limitations of current models in mind, we thought it
was essential to attempt to improve the P. falciparum humanised
mouse model, particularly in terms of control of inflammatory
reactions, and reproducibility of parasitemia. We decided to
address these issues by using the IV route for huRBC and parasite
administration, and by investigating other means to increase
control over the mouse innate immune response. The use of this
IV model led us to identify, among several factors investigated, the
effect of aging and that of inosine as significant in reducing
inflammatory reactions, and therefore improving P. falciparum
growth. Moreover, after using various strains of immunodeficient
mice, we investigated, as others [14], the value of the NOD/
SCID/IL-2Rc-null mouse (NSG mouse) which, due to the knock
out of the c-chain of the IL-2 receptor, has been shown to better
tolerate a variety of transplanted human cells [15,16,17,18].
The resulting new IV model using NSG mice presents several
significant advantages over previously available models. It offers
greater reproducibility, with 100% of mice successfully grafted
without the need for mouse-adapted parasites, consistent curves of
parasitemia, and high levels of infection with up to 40–50% of
total erythrocytes infected.
Materials and Methods
1. Mice
All procedures were carried out in line with the European
Community Council Directive, 24
th November 1986 (86/609/
EEC), and the European Union guidelines. All procedures were
reviewed and approved by the Pasteur Institut Animal ethical
committee (approval number A 75 15–27). Every effort were made
to minimize suffering.
BALB/c, NOD/SCID and NSG mice were purchased from
Charles River. Immunodeficient mice were kept in sterile isolators.
They were housed in sterilized cages equipped with filter tops
during the experimentation, and they were provided with
autoclaved tap water and a c-irradiated pelleted diet ad libitum.
They were manipulated under pathogen free conditions using
laminar flux hoods.
2. Human Red Blood Cells (huRBC)
Human whole blood was provided by the French blood bank
(Etablissement Franc ¸ais du Sang, Paris, France) and used in
accordance with French legislation. Blood donors had no history
of malaria and all blood-groups were used without observing any
difference on parasite survival. Whole blood was centrifuged thrice
at 9006g, for 5 minutes at room temperature and the buffy coat
was separated in order to eliminate white blood cells and platelets.
Packed RBC were suspended in SAGM (Adenine, Glucose and
mannitol solution) and kept at 4uC for a maximum of 2 weeks.
Before use, huRBC were washed three times with RPMI-1640
medium (Gibco/BRL, Grand Island, N.Y.), supplemented with
1 mg of hypoxanthine per liter (Sigma, St Louis, MO) and
warmed at 37uC.
Blood samples drawn from mice were used to determine the
percentage of huRBC in mouse peripheral blood at regular
intervals by flow cytometry on a FACScalibur (BD biosciences)
using FITC labeled anti-human glycophorin monoclonal antibody
(Dako, Denmark).
3. Parasites
P. falciparum lines 3D7, UPA, and K1 were employed in this
study, along with one clinical isolate taken from a patient at Bichat
Hospital, Paris (used the day after sampling). The Uganda Palo
Alto (UPA) strain employed was the Palo Alto Marburg line, this
was used for all experiments conducted unless otherwise specified.
Parasite cultures were not synchronized and therefore a mix of
various developmental stages was injected to infect mice. Parasites
were maintained under in vitro conditions at 5% hematocrit at
37uC in a candle jar in complete culture medium (RPMI-1640
medium (Gibco/BRL), 35 mM HEPES (Sigma), 24 mM
NaHCO3, 10% albumax (Gibco/BRL) and 1 mg of hypoxanthine
(Sigma) per liter. Parasite samples were cryopreserved using the
glycerol/sorbitol method [19]. The cultures were controlled for
Mycoplasma contamination by using PCR testing.
4. Mouse infection and immunomodulation protocol
NOD/SCID mice were retro-orbitally injected with 400 ml
huRBC every 3 days to ensure a satisfactory proportion of huRBC
(i.e. chimerism), at the time of infection (<60%). Simultaneously,
0.1 ml of unsized dichloromethylene diphosphonate (Cl2MDP)
encapsulated in liposome (clo-lip) (provided by Nico Van Rooijen)
diluted in 0.4 ml RPMI was intraperitoneally injected. Four
injections at 2–3 day intervals were given before parasite infection.
At the time of the fifth injection, mice were retro-orbitally injected
with 300 mlo faP. falciparum infected huRBC suspension in RPMI
at a parasitemia of 1% (all the developmental forms, i.e. rings,
trophozoites and schizonts were present). After infection huRBC
and clo-lip were supplied every 3 days as described for the pre-
infection step. In some experiments, 250 mg/kg of inosine (Sigma)
was injected intraperitoneally every day as the half-life of inosine is
very short [20].
In experiments using NSG mice the protocol has been adapted
in order to achieve varying levels of adequate huRBC chimerism
and to avoid overloading the mice. As such, different amounts of
blood were employed, and either 200, 400, 550 or 750 ml huRBC
was injected 3 times per week (i.e. Monday, Wednesday and
Friday) mixed with 250 ml human AB serum, as it has previously
been described that human serum improves huRBC survival in
immunocompromised mice [11]; 4 injections were done pre-
infection, and clo-lip was injected as described above. Follow-up of
the infection was performed by daily Giemsa stained thin blood
films drawn from the tail vein.
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In NOD/SCID mice inflammation was induced by IP injection
of 1 ml 3% thioglycolate (Sigma) diluted in sterile PBS. 4–5 days
after, the peritoneal cavity was washed with HBSS without Ca
2+
and Mg
2+. The collected cells were washed twice in RPMI
supplemented with L-glutamine, Penicillin (100 U/ml), Streptomy-
cin (100 mg/ml), and 10% Fetal Calf Serum (FCS) and seeded at
3610
5 per well in a 96-well culture plate. Single cell suspensions of
splenocytes were prepared in cold RPMI 1640 medium supple-
mented with 10% FCS and filtered on a 100 mm cell strainer to
remove debris. Erythrocytes were lysed with ACK lysis buffer, and
the splenocytes were washed 2 times with RPMI supplemented with
10% FCS and seeded at 3610
5 per well of a 96 well culture plate.
6. Cytokines/chemokine/chemiluminesence assay
100 ml blood samples were collected from the retro-orbital
plexus with a Pasteur pipette, and sera were stored at 280uC.
Conditioned media obtained after 16 h stimulation of peritoneal
cells and splenocytes with lipopolysaccharide (LPS, 1 mg/ml)
(Sigma) were stored at 280uC. Cytokines and chemokines (IL-6,
MCP-1, IFNc, TNFa, IL-12p70 and IL-10) were quantified using
the BD
TM Cytometric Bead Array mouse inflammatory kit (BD
biosciences) following the manufacturer’s recommendations on a
FACScalibur (BD biosciences).
Since production of reactive oxygen intermediates (ROI) closely
mirrors the state of activation of macrophages and polymorpho-
nuclear cells, luminol dependent photometric assay was used to
measure ROI. Blood samples were collected from NOD/SCID
mice, washed with HBSS with freshly added Ca
2+ and Mg
2+.
Washed blood was diluted 1/10 in HBSS and 90 ml blood was
added to each well in a 96 well plate (Nunc, Denmark) and
incubated for 30 minutes at 37uC after adding 10 ml PMA (final
concentration 1 mg/ml) to stimulate the cells. 50 ml of luminol
(final concentration 200 mg/ml) solution was added immediately
before measuring emissions.
7. Analysis of deep-seated organs for parasite differential
count
NSG mice were used for the comparison of parasite differential
counts in the peripheral blood, with that in deep-seated organs.
Four mice were infected with UPA strain, and when a parasitemia
of .10% was reached, a thin smear from peripheral blood was
made before killing the mouse, and harvesting its organs. Kidney,
liver, spleen, lung, and brain were removed from each mouse.
Parasite content was assessed from blots made by repeatedly
spotting sections from each organ. These slides were then stained
with Giemsa. The last blots taken were considered to be the most
representative of the parasite content in the organ’s vascular bed,
and were examined at 1000x magnification to perform differential
counts of each stage (.200 parasites from each organ counted).
Results
Development of an IV model
In a previous study [6], we have shown that among NOD/
SCID mice inoculated intraperitoneally with huRBC and P.
falciparum (IP-IP model), the majority do not support a stable and
sustained peripheral blood parasitemia. For this reason we
attempted to develop a new model in which both huRBC and
P. falciparum are directly injected into the mouse blood stream (IV-
IV model). With this IV protocol 100% of NOD/SCID mice
proved to be parasitized by day 1 post-inoculation vs only 56%
using the IP protocol (data not shown). Despite this marked
improvement, among the 59 mice treated with the standard
immunomodulatory protocol of innate defences (clo-lip), the
parasitemia duration was short (average 5.5 days) and parasitemia
was stable for $12 days in only 5 mice (Figure 1).
We sought to better understand this large variation in duration
of parasitemia. It was not explained by differences in chimerism.
However, close analysis did show a significant difference in
parasitemia duration between young mice and aged mice.
Figure 1. Effects of aging and inosine on parasitemia in NOD/SCID mice. Parasitemia is shown as a percentage of total erythrocytes found in
mouse peripheral blood measured on giemsa-stained thin smears. Levels are shown for old mice (.15 weeks) receiving inosine (green) or without
inosine (yellow) and young mice (,15 weeks) with inosine (red) or without (blue). P. falciparum 3D7 strain was inoculated on day 0. A 400 ml pellet of
huRBC and clo-lip (100 ml) were administered (IV and IP respectively) 3 times a week to all mice. For the inosine groups, inosine (250 mg/kg) was
administered IP daily. Results represent the mean 6 SEM from 11 different experiments, positive result/success means parasitemia lasting .12 days
a) green curve: n=41, 15 positive, 36,6% success, b) yellow curve; n=30, 5 positive, 16,6% success; c) red curve; n=29, 0 positive, 0% success; d) blue
curve; n=10, 1 positive, 10% success.
doi:10.1371/journal.pone.0018045.g001
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We define young mice as those less than 15 weeks old and old
mice as greater than 15 weeks old. While 16.6% of the aged mice
were able to support a parasitemia lasting more than 12 days, none
of the young mice supported a parasitemia lasting this long, and
average length of parasitemia for old vs young was 7.1 vs 3.9 days
respectively. The gender of the mice made no difference.
To explain this phenomenon, we analysed the inflammatory
responses of healthy non-infected ‘‘young’’ and ‘‘aged’’ NOD/
SCID mice. The levels of inflammatory mediator production were
investigated in peritoneal cells and splenocytes from these mice in
vitro after stimulation with LPS for 16 hours. The levels of IL-6,
MCP-1, TNFa and IFNc were 1.7, 2.8, 1.8, and 6.4 times lower in
the supernatant of peritoneal cells from aged mice as compared to
that from young mice, respectively. Despite these important
differences, probably due to group size, they were not statistically
significant. The same investigation was performed using spleno-
cytes, and the findings were more modest. The levels of IL-6,
MCP-1, TNFa and IFNc were 1.18, 1.16, 2.14 and 1.54 times
lower in supernatants of splenocytes from aged mice as compared
to young mice, respectively (Figure 2A). Interestingly, cells from
young mice produce very strong inflammatory responses when
incubated in serum from young mice, whereas these responses are
decreased when they are incubated in serum from old mice. This
would imply that these age-related differences are mediated by
humoral factors.
Furthermore, a study of O2- free radical emission from PMA-
stimulated peritoneal cells detected by chemiluminescence showed
major differences for young vs aged mice cells, i.e.: 11046354 vs
3086152 CU respectively, and in splenocytes 21006941 vs
13986528 CU respectively. These findings were not statistically
significant either, however (Figure 2B).
The same was addressed in P. falciparum infected NOD/SCID
mice using serum collected 1, 3 and 6 days post-inoculation, either
from young mice with short-lived parasitemia or aged mice with
long-lasting parasitemia. Among the cytokines/chemokines mea-
sured only IFNc differed, particularly on days 1 and 3 (102638 vs
4546168 at day 1, and 2468 vs 3696196 at day 3, in aged vs
young mice, respectively) (Figure 2C).
Effect of immunosupressants on NOD/SCID mice
In order to improve sustainability of parasitemia in the mouse
model further, we investigated immunosuppressive agents that
might help to minimize the innate immune response. Inosine, a
purine nucleoside, proved to be the most effective agent at
improving peripheral blood parasitemia from a group of agents
tested, including TGFb1, dexamethasone, and IL-10.
In vitro experiments found that at a concentration of 1 mM
inosine decreased IL-6, MCP-1, and TNFa secretion from young
NOD/SCID LPS stimulated peritoneal cells by a ratio of 1.72,
3.55, and 2.56 respectively as compared to similar inosine-
untreated cells. This effect was less pronounced on cells from aged
mice, with respective decreases of 1.23, 1.49, and 2.24, although
age related differences were not significant (Figure 3). The other
cytokines/chemokines tested (IL-12p70, IFNc and IL-10) re-
mained unchanged. In the case of NOD/SCID mouse spleno-
cytes, only IFNc release was decreased by treatment with inosine
in vitro. The reduction of IFNc production in young and aged mice
was 2.3 and 1.7 times respectively.
In vivo inoculation of inosine confirmed the above data in both
young and aged mice. In young NOD/SCID mice daily intra-
peritoneal injection of inosine at a dose of 250 mg/kg led to 10% of
mice sustaining parasitemia for .12 days, as compared to none in the
inosine-free group. Using the combination of aged mice and inosine
administration resulted in 37% of mice sustaining parasitemia for
.12 days, and an average length of parasitemia of 9.8 days.
Development of an improved IV model using NSG mice
Experiments were performed in NSG mice using various
amounts of huRBC (200, 400, 550 or 750 ml of RBC pellets)
injected IV 3 times a week, and also using the IV route to
introduce the parasite infection. Clo-lip was delivered IP on the
same day as huRBC administration. This is called the NSG-IV
model below.
Injecting 750 ml of huRBC resulted in a high proportion of
huRBC in mouse peripheral blood (chimerism), ranging from 83%
to 92% of total erythrocytes (Figure 4A). This high level of
chimerism was stable over a number of months and supported
rapid, optimal growth of P. falciparum (Figure 4B) with abundant
and very healthy parasites (Figure 5). Indeed peripheral blood
parasitemia levels reached 30–35% within 3 weeks (Figure 4B) and
went on to reach a maximum of 56.2% (which corresponds to a
parasitemia of 67% in the huRBC subset of mouse peripheral
blood). The total haematocrit in mouse peripheral blood was on
average 70% using this protocol (data not shown).
Use of a lower dose of huRBC (400 ml) resulted in an initial
chimerism of about 60% (Figure 6A), and parasitemia of up to
7.2% (ca. 12% of huRBC parasitized). Use of this lower huRBC
volume however, was followed by a decrease in chimerism most
likely due to inflammation induced by the parasite, producing a
parallel reduction in parasitemia, which fluctuated at an
intermediate level, i.e. without complete parasite clearance
(Figure 6B).
An analysis of inflammatory markers was performed in mice
from the latter protocol to investigate the observed decrease seen
in chimerism. The results revealed substantial differences from
NOD/SCID mice. The decreased huRBC chimerism and
parasitemia seen in NSG mice correlated with the release of
TNFa and IL-12p70. In contrast IL-6 and IFNc remained almost
unchanged (Figure 6B), whereas in NOD/SCID mice IL-6 and
IFNc levels increased at the time of parasite decrease [6]. Hence
the inflammation produced by NSG mice is reduced in
comparison to that seen in NOD/SCID, and this is likely to be
one of the reasons for improved P. falciparum survival.
We observed from the variety of protocols experimented with,
that provided the chimerism is maintained above 10–20%,
parasitemia can be supported for a number of months (i.e. the
mouse life-span). So, to avoid volume overload in the mice,
intermediaryprotocolsweredesignedrequiringlowervolumesofIV
administeredhuRBC:i)satisfactoryresultswere achievedinallmice
where 550 ml of huRBC was injected three times a week (n=47),
witha mean 6 SD chimerism of 74%67% over the first month and
half, decreasing to 56% over the second and third month, and long-
lasting parasitemia reaching up to 20–40% (25.6% to 51.3% of
huRBC parasitized); ii) when 550 mL of huRBC was injected only
twice a week, a chimerism of 40–60% was achieved and this
supported a moderate 5%–12% parasitemia during the first month.
In this manner, adjusting the quantity of huRBC injected leads
to various levels of prolonged, stable parasitemia. The level can be
tailored in this manner to the needs of each experiment.
In this model there was no need for preliminary adaptation of
the parasites, contrary to what has been reported for another
model based upon the NSG mouse [11]. All strains tested were
supported (UPA, 3D7, K1), and parasite growth was readily
apparent from the first days post-inoculation. Naturally, there
were some variations in the maximum parasitemia reached with
each strain, particularly for 3D7, which produced the lowest. Mice
were also infected with a fresh clinical isolate of P. falciparum. With
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forms for the first 4 days, then trophozoites appeared as the
parasitemia rose from 0.1 to 1%. Each of the 2 animals infected
showed satisfactory growth as did mice sub-inoculated with
parasites from the initial animals (not shown).
Mice used in the NSG-IV model, when the 550 ml dose is given,
demonstrated a life expectancy equivalent to, or slightly better
than that seen in NOD/SCID mice used for previously described
models (i.e. 2–3 months).
The NSG-IV model was reliably reproducible. All mice grafted
with huRBC and infected with P. falciparum to date developed a
peripheral blood parasitemia (n=68). The degree of chimerism
and parasite growth was consistent and homogenous from one
animal to the other (see Figure 4B). This is a critical difference
from the SCID, BXN or NOD/SCID models [6,7,8,10].
To confirm the advantage of the IV route, the same NSG mice
were used in a protocol using intra-peritoneal (IP) grafting of
huRBC, and IP infection with P. falciparum. Despite the advantage
of a decreased inflammatory response in this strain of mice, this
‘‘IP-IP’’ protocol provided erratic outcomes, with large individual
variations from one animal to the other in terms of presence of
parasites in peripheral blood (data not shown). Ultimately, the IP-
IP protocol in NSG proved to be as inadequate, and as
troublesome as the same route in NOD/SCID.
The value of inosine was re-addressed in NSG. In experiments
performed using the 400 ml huRBC dose, inosine was administered
Figure 3. Effect of inosine and the aging process on production of inflammatory mediators in NOD/SCID mice. Determination of levels
of cytokines in supernatants of peritoneal cells (IL-6, MCP1, TNFa) or splenocytes (IFNc) collected from NOD/SCID mice and stimulated in vitro with
LPS (1 mg/ml). Results from cells of aged mice (.15 weeks) and young mice (,15 weeks) incubated with or without 1 mM inosine are shown. Results
represent the mean 6 SEM from an experiment performed using 3 mice per group.
doi:10.1371/journal.pone.0018045.g003
Figure 2. Effect of the aging process on the production of cytokines in NOD/SCID mice. Panel (A): levels of various inflammatory
mediators (IL-6, MCP-1, TNFa, IFNc) in supernatants of peritoneal cells (n=10) and splenocytes (n=16) from young vs aged mice after stimulation
with LPS (1 mg/ml) ; Panel (B) : levels of reactive oxygen intermediates, measured by chemiluminescence, in the presence of PMA (10 mg/ml)
produced by peritoneal cells (n=4) and splenocytes (n=5) taken from young vs aged mice; Panel (C): in vivo levels of IFNc in aged mice (with long-
lasting parasitemia) (n=4) compared to young mice (with short-lived parasitemia) (n=5) as measured in serum samples collected 1, 3, and 6 days
post infection with P. falciparum. Cytokine levels were measured by using the CBA mouse inflammatory kit by FACS. Results represent the mean 6
SEM from two different experiments.
doi:10.1371/journal.pone.0018045.g002
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the benefits of inosine on parasite survival were initially not as
obvious as in NOD/SCID mice, statistically significant improve-
ment of parasitemia in NSG mice receiving inosine (n=3), as
compared to NSG without inosine (n=4), became apparent (Figure
S1) after about 2 weeks of treatment, i.e. when strong inflammatory
responses are induced by high parasitemia (non parametric
Wilcoxon test on 55 paired values: Z=3.65, p value=0.0003).
Additional characteristics of P. falciparum in the NSG-IV
model
Remarkably, parasite growth occurred in a synchronous fashion
(Figure 4C and Figure S2), with the vast majority of parasites in
peripheral blood being at the same stage at a given time (Figure 5).
As shown in Figure 5 A, B, C, D, over 95% of parasites were
simultaneously either at young ring stage or at trophozoite stage.
This resulted in a stepwise increase in parasitemia. As demon-
strated in Figure 4C, over the first 24 hours the parasite matures
without an increase in parasitemia. This is then followed the next
day by the reinvasion of new huRBC, leading to a steep increase in
the proportion of infected erythrocytes (Figure 4C and Figure S2).
As asynchronous parasite cultures were used to infect animals, this
suggests a synchronizing effect of the mouse innate defences. This
is the first-ever animal model for P. falciparum that exhibits a
synchronised asexual blood stage cycle as occurs in human beings.
However this characteristic was not constant, in particular when
there was long-standing high parasitemia; this synchronism
eventually disappeared in some of the mice as illustrated in Figure
S3.
Fully mature schizonts, i.e. segmenters, were seen very rarely in
peripheral blood and this occurred mostly at high levels of
parasitemia. However, the high rate of re-invasion implied that
they were developing and releasing merozoites in a synchronised
manner elsewhere.
To investigate this further we analyzed the parasite stages in
peripheral blood, as compared to those in deep-seated capillary
beds from various organs. In peripheral blood segmenters were
only seen rarely when parasitemia was low, particularly during the
initial increase following infection of mice, i.e. ,1% of all parasites
detected. When the parasitemia increased, their proportion slightly
increased, i.e. reaching 3–5% of those huRBC parasitized. Among
all parasites seen, the majority were rings or very mature
pigmented trophozoites (parasites at a single nucleus stage). The
very mature trophozoites seen did not differ in morphology from
similar stages that can be appreciated in peripheral blood from a
malaria patient. The simultaneous presence of 3–4 mature
trophozoites in the same RBC (Figure 5C and D) sometimes can
be mistaken for a schizont. Schizonts were present however, but
were only seen rarely.
The parasite load in blood from various organs investigated was
similar to that seen in peripheral blood at the time of sampling.
However capillary blood from the brain, kidney, spleen, and liver
revealed a 4–5 fold higher proportion of segmenters (detailed
counts of brain and kidney showed that 14–16% of parasites were
fully mature schizonts, at a time when the peripheral blood
contained only 3% of them). Tissue sections examined by IFAT
using an anti-HSP antibody also revealed numerous pigmented
mature forms in the organs; however it was not possible to perform
a differential count as rings were hardly identified at all by this
means (not shown). These findings are suggestive of an
intermediate level of sequestration in the NSG-IV model, with
high numbers of very mature trophozoites and occasional presence
of schizonts in peripheral blood, but with markedly higher
prevalence of mature schizonts in organ vascular-beds.
Gametocytes were also able to develop in the NSG-IV model.
These sexual forms (Figure 5G, H) were occasionally seen up to
stage III or IV, and developed rarely to stage V. The observation
of stage V gametocytes implies that infected huRBC are able to
survive in the mouse circulation for, at least, 9 days without
suffering any significant immune-mediated insults when the NSG-
IV protocol is used.
Discussion
This study is part of our longstanding effort aimed at creating a
satisfactory experimental mouse model for P. falciparum malaria. By
employing the IV route for both parasite and huRBC delivery,
Figure 4. Results obtained using the NSG-IV P. falciparum
model. Panel (A): proportion of huRBC (% of total erythrocytes), or
‘‘chimerism’’ seen in peripheral mouse blood, as determined by FACS
analysis using an anti-human glycophorin A antibody (average of 18
mice). HuRBC grafting started 10 days before infection with P.
falciparum; Panel (B): parasitemia patterns obtained after inoculation
with either UPA (red; n=10), 3D7 (blue; n=4), or K1 (green; n=4) P.
falciparum strains. Results represent the means 6 SEM from 2 different
experiments. Panel (C): detailed pattern of P. falciparum growth over
time in the NSG-IV model. Arrows indicate points at which .95% of
parasites were at ring stage. Parasitemia is expressed as a percentage of
total erythrocytes found in mouse peripheral blood. Mice received
750 ml of huRBC delivered IV 3 times a week, along with IP
administration of liposomal clodronate (100 ml).
doi:10.1371/journal.pone.0018045.g004
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mutation on the NOD/SCID genetic background, we have
achieved a model that has 100% reproducibility, is receptive to
numerous strains without requiring pre-adaptation of the parasite,
and supports fast-rising, high-reaching P. falciparum parasitemia
that remains stable for weeks or months.
Results also show that the pro-inflammatory effect of P.
falciparum is better controlled, however still suboptimally. In
addition to clodronate encapsulated liposomes (clo-lip) [6], we
now demonstrate, in NOD/SCID mice, the immunomodulatory
effects of aging, of inosine and of the IL-2 receptor c mutation.
The latter brings the greatest breakthrough with a marked
reduction in inflammatory cytokines/chemokines and, most likely
for this reason, improved P. falciparum survival. Results are in
keeping with those reported recently using an hybrid IP-IV model
and an immunodeficient mouse-adapted P. falciparum strain [14].
The combination of an IV-IV protocol and prudent use of
immunosuppressive factors has produced a model that has a
number of attractive features over those previously described.
The main advantage is an extremely high success rate, with
100% of mice that were infected showing a healthy P. falciparum
parasitemia. This represents a dramatic improvement compared
to the low proportion of mice with stable parasitemia that we
obtained in previous models [6,8]. By using the IV route and clo-
lip we reduced huRBC requirements and above all excluded the
unpredictable, poorly understood transperitoneal passage of
huRBCs as employed in existing models [6,11,21].
Another advantage is the high reproducibility. The parasitemia
curves were very consistent from one animal to the other with low
standard deviations, a feature that will be important when using
the model for vaccine or drug studies. This level of consistency is,
in fact, more so than what is seen in human infections where
untreated cases show day-to-day variations in parasitemia by one
degree of magnitude or more [22]. The parasitemia is also capable
of reaching high levels of density, particularly when calculated as a
percentage of the huRBC subset rather than total erythrocytes.
These favourable characteristics of the model are complemented
by a rapid rate of parasite growth, which rises faster than in other
models [6,9,21], with very healthy looking parasites and frequent
polyparasitism of huRBC.
Several results concur to suggest that the model is closer to
events recorded in humans than other existing P. falciparum models,
namely receptivity to non-adapted parasites, synchronisation,
partial sequestration of mature forms and gametocyte production.
All P. falciparum strains tested so far have been supported,
indicating that, in contrast to Aotus, Saimiri and previous mouse
models, there is no requirement for preliminary adaptation of the
parasite to this new host [11,14,23,24,25]. This was true for the 3
strains employed and for one clinical isolate of P. falciparum tested.
Results obtained with the latter bode well for the potential of the
model to support P. vivax growth.
This is the only Malaria model that has ever demonstrated the
phenomenon of synchronisation, which is not seen either in Aotus,
Saimiri, or other immunodeficient mice [11,14,23,24,25]. Exam-
Figure 5. Examples of parasitemia obtained in the NSG-IV model. Panels (A) and (B) illustrate the typical predominance of ring stage
parasites seen at 48 h intervals (see Fig. 4 C and SI-II), with frequent polyparasitism. Such parasite densities are common using UPA parasites in mice
having .75% chimerism. Panel (C) fully mature trophozoites seen 24 hours later, as compared to A and B. Single nucleus trophozoites predominate,
though some can be mistaken for schizonts due to polyparasitism. However rings and young schizonts are also present in small proportions. Panel
(D) illustrates one of the highest parasitemias obtained. Insert: active phagocytosis by a circulating monocyte. Panels (E) and (F) illustrate fully mature
schizonts which are only occasionally seen in peripheral blood. Panel (G) stage IV gametocyte, Panel (H) rare occurrence of mature gametocyte (stage
V) in peripheral blood.
doi:10.1371/journal.pone.0018045.g005
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being at the same stage. This synchronisation results in a very
characteristic step-wise increase in parasite density at 48 hour
intervals - reminiscent of tertian Malaria - at least during the initial
rising phase. The various stages seen in the peripheral blood do
not differ morphologically from those that are observed in human
peripheral blood smears, although very high densities of mature
trophozoites can be seen in NSG which, obviously, is seldom seen
in humans.
Partial sequestration takes place with an overwhelming
dominance of rings or mature trophozoites (i.e. parasites at one
nucleus stage) in peripheral blood, and conversely rare schizonts.
However the presence of schizonts seems to increase at high
parasitemia. Examination of blood from deep-seated capillary
beds from various organs shows that the most mature segmenters
are far more frequent, ca. 4–5 fold, in blood from the brain and
the kidney, than in peripheral blood. This partial sequestration
could result from sub-optimal affinity of the P. falciparum infected
huRBC for the heterologous murine endothelium. Conversely
mature forms are also occasionally seen in human peripheral
blood particularly in severe cases at high parasite loads [26]. Thus,
it is also possible that at high parasite loads, phagocytosis of
numerous parasites by neutrophils results in neutrophil necrosis,
causing release of neutrophil proteases, which together with
parasite proteases, may in turn contribute to desequestrate mature
forms from the endothelium [27]. Whatever the case, the picture
that emerges is one of intermediate, rather than absolute
sequestration. Further work will be required to determine if the
model can help understand the sequestration phenomenon which
is characteristic of P. falciparum, and to see if it has relevance to the
human situation.
The model also proved to support the development of the P.
falciparum sexual blood cycle. Stage III and IV gametocytes could
be seen in the peripheral blood; however stage V gametocytes
were rarely seen, most likely as a result of the high turnover rate of
huRBC caused by the residual inflammatory response, and the
long duration needed for the sexual blood cycle.
From a practical point of view the described NSG-IV model is
very flexible, and levels of parasitemia can be adjusted, by
modulating the amount of huRBC injected, to anywhere from 1–
2% to 30–40% in order to meet the needs of the experiment, and
of the investigator. The model remains demanding however, with
2–3 IV inoculations required per week.
Results also show, that innate defences are still very active and
hence that the model remains suboptimal. Detailed analysis better
defined the role of each of the cytokines/chemokines produced in
this process, and helps to identify which ones need to be controlled
to improve success. Our findings contribute in this way to the
understanding of the delicate balance between inflammation
control and P. falciparum survival.
The relationship between aging and the mouse’s ability to both
tolerate the graft and produce less inflammatory mediators is an
interesting finding that emerged from the analysis. Aging is well
known to be associated with increased susceptibility to infections
Figure 6. Residual inflammation present in the IV-NSG model. Panel A: using the sub-optimal dose of 400 mL huRBC grafting results in a
reduction of chimerism (red line) and parasitemia (blue line); Panel B: inflammatory cytokine responses were measured in parallel using the CBA kit.
Note the initial rise of IL6, followed by a major increase of IL-12p70, and a modest increase of TNFa and MCP-1 that are temporally associated with
anemia, and might play a role in its etiology. Results represent the means 6 SEM from 2 experiments (n=7).
doi:10.1371/journal.pone.0018045.g006
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on the immune system, both adaptive and innate. Several recent
studies have described modifications of immune function in aged
subjects, leading either to increased, or more frequently decreased
inflammatory processes with a reduction in LPS-induced IL-6, and
IFNc levels, similar to what we observed [30,31,32,33]. However
we are not aware of any previous data pertaining specifically to
NOD/SCID mice. The present findings of improved graft survival
associated with a decreased release of inflammatory cytokines by
macrophages in ‘‘aged’’ mice complements previous findings in
other mouse strains [34], and indicates that this process reduces
defences against Plasmodium. The effect of aging was not evident in
the NSG mice however. This is likely to be due to a blurring of the
effect by interposition with the IL-2Rc mutation, along with a
sample size too small to show a marginal benefit of aging in these
mice.
Among a large number of immunomodulating substances
investigated, inosine emerged as one of the few drugs beneficial
in this scenario. It is well known that adenosine possesses anti-
inflammatory properties [35], and that its derivative analogues
such as inosine, can provide protection to mice from a variety of
inflammatory diseases including endotoxic and septic shock
[35,36], acute lung injury [20,37], pleural inflammation [38],
and colitis [39] by inhibiting the release of free radicals and pro-
inflammatory cytokines [40]. Inosine, a naturally occurring
purine, and breakdown product of adenosine by adenosine
deaminase [41], has been shown to have both pro and anti-
inflammatory properties, probably mediated by its ability to bind
to more than one type of adenosine receptor. The results of the
present study showing that inosine reduces the release of IL-6,
MCP-1 and TNFa by macrophages from NOD/SCID mice, is
consistent with previous reports using cells from immunocompe-
tent mice [42]. These effects are supported by the significant
improvement that was seen in parasitemia for mice that received
inosine, compared to those that did not. Inosine may also act
through its ability to suppress the function of neutrophils. It has
been reported to inhibit neutrophil recruitment in vivo, and inhibit
neutrophil superoxide production in vitro [40]. While the effect of
increasing age on an NSG background was not evident, the benefit
of administering inosine was significant at high parasitemia, i.e.
after 15 days of treatment.
The relationship observed in this study, as in our previous study
[6], between the peak of inflammation and a reduction in huRBC
count should be stressed. It suggests that the anemia seen
correlates with increased inflammation, and that it could
potentially be the inflammation itself that causes the anemia,
independent of the parasite, through destruction of non-infected
huRBC. This might be mediated by free oxygen radicals
damaging the huRBC membrane [43]. In this respect the model
may provide novel research hypotheses that could lead to better
characterize the poorly understood pathophysiological process of
severe anemia in humans, which is one of the two major causes of
mortality [44], although admittedly the human situation differs
substantially from that of P.falciparum in the NSG mice.
Our results confirm that the NSG mouse strain has a
significantly attenuated inflammatory response, leading to an
improvement in parasitemia. These mice have proven to be
excellent hosts for the grafting of various human cells, and notably
they are better recipients than NOD/SCID for CD34+ hemato-
poietic stem cells and human leukocytes [15,18,45]. This improved
receptivity results from the reduced function of macrophage and
dendritic cells, in addition to the lack of T, B, and NK cells
[18,45]. The improved survival of P. falciparum in NSG was
associated with an absence of significant production of the two
major inflammatory cytokines IL-6 and IFNc, whereas both were
elevated in the NOD/SCID model [6]. This is not to say that the
inflammatory response was quashed completely in the NSG strain.
The need for further efforts to control the deleterious responses of
the murine immune system in this model remains, likely by
including additional genetic modifications, for example, by
knocking out CCR2 on an NSG genetic background to reduce
the egress, the recruitment and the number of inflammatory
monocytes [46,47,48].
The improved survival of P. falciparum in NSG mice is in
agreement with results recently reported by Jime ´nez-Dı ´az et al.,
where massive loads of huRBC were administered intra-peritone-
ally [14]. At the expense of injections on a daily basis of as much as
2 ml of blood (1 ml huRBC pellet) IP in 25 gram mice, and using a
mouse adapted strain of P. falciparum, improved results as
compared to NOD/SCID/b2m mice [11] were obtained. The
fact that the mice were able to survive such severe treatment
implies that there must have been massive intraperitoneal
destruction, and intravascular hemolysis of grafted erythrocytes.
Inflammatory mediator levels were not reported for this IP model
however, and it is unclear how the huge huRBC loads operate. It
has been reported in patients receiving blood transfusions, that
large amounts of RBC can exert an immuno-suppressor effect
upon macrophages [49]. It is also possible that macrophages
overloaded by phagocytosis of an inordinate number of huRBC
become unable to cope with additional parasitized cells. Similarly,
by saturating the mouse with huRBC, a subset of them sufficient to
permit P. falciparum development is more likely to remain intact,
despite the massive amount of erythrocyte destruction. Whichever
way, we repeated the protocol described by Jime ´nez-Dı ´az et al
[14] and confirm their results (not shown).
The use of liposomes containing clodronate (clo-lip), as
described in the macrophage ‘‘suicide’’ approach developed by
Nico van Rooijen [50,51] brings several advantages with respect to
both parasite survival and the quantity of huRBC that need to be
administered. The reduction in macrophage numbers induced by
clo-lip, and its consequence on parasite survival has been
described in previous work on NIH-III and NOD/SCID mice
[6,7]. In our NSG-IV murine model, clo-lip complemented the IL-
2Rc mutation very nicely in controlling inflammation, and thereby
reducing erythrophagocytosis. For example, using this drug
allowed us to reduce the total number of huRBC injected into
mice by nearly 5 times as compared to the IP-IV model [14], i.e. a
total of 1.6 ml vs 7 ml per week, per mouse (or nearly 10 times, i.e.
only 0.8 ml vs 7 ml when a moderate parasitemia is desired),
avoiding overload of the peritoneal cavity with [13] unreasonable
volumes of fluid, proteins, membranes and the local pathological
consequences.
In total, there are now three possible protocols that can be used
in NSG mice, each with different outcomes. They differ in the
routes of delivery used for huRBC and parasites - in the ‘‘IP-IP
model’’, both components are delivered intraperitoneally; in the
model employed by Jime ´nez-Dı ´az et al. the former are delivered
intraperitoneally while the infection is delivered intravenously
leading to the ‘‘IP-IV model’’; and in this study we demonstrate
the ‘‘IV-IV model’’ where both components are delivered
intravenously. The IP-IP model presents the same limitations as
were described when using this protocol in NOD/SCID mice,
with poor reproducibility of peripheral parasitemia. The IP-IV
model remains effective at the expense of administering large
amounts of huRBC to the mouse, daily interventions, and pre-
adaptation of the parasite. Therefore, the IV-IV model seems to
be more physiological, requiring lower amounts of huRBC and
only 2–3 interventions per week. The requirement for 3 injections
Improved P. falciparum Mouse Model
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should be replaced in the near future by a model harbouring a
hematopoietic stem cell line capable of producing human
erythroblasts/cytes [52], with the advantage of producing
reticulocytes to also support P. vivax [53].
The main advantages of the NSG-IV model are that it offers
extremely high reproducibility of both huRBC grafting and
parasite survival, a rapidly rising parasitemia that reaches high
levels, for long durations, and it does not need preliminary
adaptation of parasite strains to the mouse. In addition, by
modulating the quantity of huRBC administered, the final
parasitemia can be adjusted to the needs of each experiment over
a range of 1–40% for several weeks, or months, in a stable,
controlled, and flexible fashion. Despite the improved behaviour
and morphology of the parasites, there is still a residual
inflammatory response that needs to be addressed in order to
optimise this model further.
Supporting Information
Figure S1 Effect of inosine on the IV-NSG model. Using
the suboptimal dose of 400 ml of huRBC, which leads to a
decrease in chimerism possibly due to inflammation as described
in Figure 6, we show that the addition of inosine at a dose of
250 mg/kg per day IP (blue line) significantly improves the
survival of P. falciparum in NSG mice compared to untreated
controls (red line). Panel A: differences in chimerism; Panel B:
differences in parasitemia on logarithmic scale; Panel C:
differences in parasitemia on arithmetic scale. Statistical analysis
using the non parametric Wicoxon ranking test of data from 3
mice (inosine) and 4 mice (controls) infected by UPA strain
showing: from day 0–15 an absence of detectable effect (n=15:
Z=21.43; P=0,152), from day 15–29, a significant difference
(n=10: Z=22,57; P=0,0101), from day 27–67, a significant
difference (n=30: Z=2.78; P=0.0053), and for all days combined
a very significant difference (n=55; Z=23.65; P=0.0003).
(TIF)
Figure S2 Further examples of synchronisation occur-
ring during the initial phase of growth of P.falciparum in
the IV-NSG mouse model, as shown by the curves of
parasitemia recorded in 3 mice, which complement data
presented in Figure 4. Arrows indicate points at which .95%
of parasites were at ring stage.
(TIF)
Figure S3 Examples of asynchronous parasitemia ob-
tained in the NSG-IV model. Following several days at high
parasitemia, the parasite cycle becomes asynchronous. In both
panels, rings and trophozoites are concomitantly present, whereas
schizonts remain rare.
(TIF)
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